ERBB2 and breast cancer: Similarly, the current guidelines for ABC specify that all suitable patients with HER2+ BC should be offered chemotherapy plus HER2-targeted therapy with trastuzumab plus pertuzumab; when chemotherapy is stopped, maintenance endocrine therapy plus HER2-targeted therapy is suggested [7,11].